Viatris announced the U.S. commercial launch of Ryzumvi 0.75% for the treatment of pharmacologically-induced mydriasis produced by adrenergic agonists or parasympatholytic agents in the United States. Ryzumvi is now the only U.S. commercially available FDA-approved eye drop to reverse dilation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTRS:
- Viatris price target raised to $13 from $11 at Piper Sandler
- Australian Stocks: CSL Shares Retain “Strong Buy” Rating from Analysts
- Viatris call volume above normal and directionally bullish
- VTRS Earnings: Viatris’ Revenue Declines in Q4; Boosts Buybacks
- Viatris sees FY24 adjusted EPS $2.70-$2.85, consensus $2.81
